Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

156 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-Term Outcomes of Biological Therapy in Crohn's Disease Complicated With Internal Fistulizing Disease: BIOSCOPE Study From GETECCU.
Barreiro-de Acosta M, Fernández-Clotet A, Mesonero F, García-Alonso FJ, Casanova MJ, Fernández-de la Varga M, Cañete F, de Castro L, Gutiérrez A, Sicilia B, Cano V, Merino O, de Francisco R, González-Partida I, Surís G, Torrealba L, Ferreiro-Iglesias R, Castro B, Márquez L, Sobrino A, Elorza A, Calvet X, Varela P, Vicente R, Bujanda L, Lario L, Manceñido N, García-Sepulcre MF, Iglesias E, Rodríguez C, Piqueras M, Ferrer Rosique JÁ, Lucendo AJ, Benítez O, García M, Olivares D, González-Muñoza C, López-Cauce B, Morales Alvarado VJ, Spicakova K, Brotons A, Bermejo F, Almela P, Ispízua N, Gilabert P, Tardillo C, Muñoz F, Navarro P, Madrigal Domínguez RE, Sendra P, Hinojosa E, Sáinz E, Martín-Arranz MD, Carpio D, Ricart E, Caballol B, Núñez L, Barrio J, Gisbert JP, Iborra M, Calafat M, Hernández V, Muñoz Pérez R, Cabriada JL, Domènech E, Rodríguez-Lago I; BIOSCOPE study group from the ENEIDA registry. Barreiro-de Acosta M, et al. Among authors: ricart e. Am J Gastroenterol. 2023 Jun 1;118(6):1036-1046. doi: 10.14309/ajg.0000000000002152. Epub 2022 Dec 14. Am J Gastroenterol. 2023. PMID: 36516073
Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case-Control Study (COVID-19-EII).
Zabana Y, Marín-Jiménez I, Rodríguez-Lago I, Vera I, Martín-Arranz MD, Guerra I, P Gisbert J, Mesonero F, Benítez O, Taxonera C, Ponferrada-Díaz Á, Piqueras M, J Lucendo A, Caballol B, Mañosa M, Martínez-Montiel P, Bosca-Watts M, Gordillo J, Bujanda L, Manceñido N, Martínez-Pérez T, López A, Rodríguez-Gutiérrez C, García-López S, Vega P, Rivero M, Melcarne L, Calvo M, Iborra M, Barreiro de Acosta M, Sicilia B, Barrio J, Pérez Calle JL, Busquets D, Pérez-Martínez I, Navarro-Llavat M, Hernández V, Argüelles-Arias F, Ramírez Esteso F, Meijide S, Ramos L, Gomollón F, Muñoz F, Suris G, Ortiz de Zarate J, Huguet JM, Llaó J, García-Sepulcre MF, Sierra M, Durà M, Estrecha S, Fuentes Coronel A, Hinojosa E, Olivan L, Iglesias E, Gutiérrez A, Varela P, Rull N, Gilabert P, Hernández-Camba A, Brotons A, Ginard D, Sesé E, Carpio D, Aceituno M, Cabriada JL, González-Lama Y, Jiménez L, Chaparro M, López-San Román A, Alba C, Plaza-Santos R, Mena R, Tamarit-Sebastián S, Ricart E, Calafat M, Olivares S, Navarro P, Bertoletti F, Alonso-Galán H, Pajares R, Olcina P, Manzano P, Domènech E, Esteve M, On Behalf Of The Eneida Registry Of Geteccu. Zabana Y, et al. Among authors: ricart e. J Clin Med. 2022 Dec 19;11(24):7540. doi: 10.3390/jcm11247540. J Clin Med. 2022. PMID: 36556155 Free PMC article.
Risk of Immunomediated Adverse Events and Loss of Response to Infliximab in Elderly Patients with Inflammatory Bowel Disease: A Cohort Study of the ENEIDA Registry.
Calafat M, Mañosa M, Ricart E, Nos P, Iglesias-Flores E, Vera I, López-Sanromán A, Guardiola J, Taxonera C, Mínguez M, Martín-Arranz MD, de Castro L, de Francisco R, Rivero M, Garcia-Planella E, Calvet X, García-López S, Márquez L, Gomollón F, Barrio J, Esteve M, Muñoz F, Gisbert JP, Gutiérrez A, Hinojosa J, Argüelles-Arias F, Busquets D, Bujanda L, Pérez-Calle JL, Sicilia B, Merino O, Martínez P, Bermejo F, Lorente R, Barreiro-de Acosta M, Rodríguez C, Fe García-Sepulcre M, Monfort D, Cañete F, Domènech E; ENEIDA Study Group of GETECCU. Calafat M, et al. Among authors: ricart e. J Crohns Colitis. 2022 Jul 14;16(6):946-953. doi: 10.1093/ecco-jcc/jjab213. J Crohns Colitis. 2022. PMID: 34864947
The Genetic Diversity and Dysfunctionality of Catalase Associated with a Worse Outcome in Crohn's Disease.
Iborra M, Moret I, Busó E, García-Giménez JL, Ricart E, Gisbert JP, Cabré E, Esteve M, Márquez-Mosquera L, García-Planella E, Guardiola J, Pallardó FV, Serena C, Algaba-Chueca F, Domenech E, Nos P, Beltrán B. Iborra M, et al. Among authors: ricart e. Int J Mol Sci. 2022 Dec 14;23(24):15881. doi: 10.3390/ijms232415881. Int J Mol Sci. 2022. PMID: 36555526 Free PMC article.
SEX-RELATED DIFFERENCES IN THE PHENOTYPE AND COURSE OF INFLAMMATORY BOWEL DISEASE: SEXEII STUDY OF ENEIDA.
Gargallo-Puyuelo CJ, Ricart E, Iglesias E, de Francisco R, Gisbert JP, Taxonera C, Mañosa M, Peris MA, Navarrete-Muñoz EM, Sanahuja A, Guardiola J, Mesonero F, Tirado MR, Barrio J, Mendoza IV, de Castro Parga L, García-Planella E, Calvet X, Martín Arranz MD, García S, Sicilia B, Carpio D, Domenech E, Gomollón F; ENEIDA registry of GETECCU. Gargallo-Puyuelo CJ, et al. Among authors: ricart e. Clin Gastroenterol Hepatol. 2024 May 21:S1542-3565(24)00487-7. doi: 10.1016/j.cgh.2024.05.013. Online ahead of print. Clin Gastroenterol Hepatol. 2024. PMID: 38782172
Cyclophosphamide-free mobilisation increases safety while preserving the efficacy of autologous haematopoietic stem cell transplantation in refractory Crohn's disease patients.
Giordano A, Rovira M, Veny M, Barastegui R, Marín P, Martínez C, Fernández-Avilés F, Suárez-Lledó M, Domènech A, Serrahima A, Lozano M, Cid J, Ordás I, Fernández-Clotet A, Caballol B, Gallego M, Vara A, Masamunt MC, Giner À, Teubel I, Esteller M, Corraliza AM, Panés J, Salas A, Ricart E. Giordano A, et al. Among authors: ricart e. J Crohns Colitis. 2024 May 17:jjae076. doi: 10.1093/ecco-jcc/jjae076. Online ahead of print. J Crohns Colitis. 2024. PMID: 38757210
Haematopoietic stem-cell transplantation in Crohn's disease.
Gupta A, Guisado D, Ricart E, Colombel JF, Cohen L. Gupta A, et al. Among authors: ricart e. Lancet Gastroenterol Hepatol. 2024 Jun;9(6):499-500. doi: 10.1016/S2468-1253(24)00055-4. Lancet Gastroenterol Hepatol. 2024. PMID: 38734002 No abstract available.
Magnetic resonance enterography findings 46 weeks after initiation of biological therapy predict long-term adverse outcomes in Crohn's disease.
Fernández-Clotet A, Ordás I, Masamunt MC, Caballol B, Rodríguez S, Gallego M, Barastegui R, Saavedra AC, Panés J, Ricart E, Rimola J. Fernández-Clotet A, et al. Among authors: ricart e. Aliment Pharmacol Ther. 2024 Jun;59(11):1435-1445. doi: 10.1111/apt.17968. Epub 2024 Apr 23. Aliment Pharmacol Ther. 2024. PMID: 38650481
Genetic biomarkers of methotrexate response and safety in Crohn's disease: Data from the Spanish ENEIDA registry.
Salazar J, Garcia-Planella E, Fernández-Clotet A, Esteve M, Gisbert JP, Busquets D, Lucendo A, Márquez L, Guardiola J, Martín-Arranz MD, Iglesias E, Monfort D, Villoria A, Cañete F, Bell O, Ricart E, Zabana Y, Chaparro M, Domènech E, Gordillo J; ENEIDA registry of GETECCU. Salazar J, et al. Among authors: ricart e. Br J Clin Pharmacol. 2024 May;90(5):1301-1311. doi: 10.1111/bcp.16017. Epub 2024 Feb 18. Br J Clin Pharmacol. 2024. PMID: 38369687
156 results